

ENDURING MATERIAL LEARNER NOTIFICATION

Med Learning Group

Enduring Evaluating Treatment Selections for Chronic Spontaneous Urticaria: Managed Care Considerations

Date of CE Release: April 20, 2022

Date of CE Expiration: April 20, 2023

Location: Online

Acknowledgement of Financial Commercial Support

Sanofi Genzyme and Regeneron Pharmaceuticals

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of 1.5 knowledge-based CPE contact hours.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Objectives - After Attending This Program You Should Be Able To

1. Quantify the economic, physical and psychosocial burden of CSU.
2. Assess treatment plans for adherence to guideline recommended therapy and consideration of patient-specific factors.
3. Evaluate clinical trial data on the efficacy and safety of available and emerging biologics for CSU.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Felecia	Beachum	NA
Jonathan	Bernstein	Consultant: Amgen, AstraZeneca, Celldex, Genentech, Novartis, Genentech, Sanofi/Regeneron; Speaker Bureau: AstraZeneca, Genentech, Novartis, Sanofi/Regeneron; Contract Research: Amgen, AstraZeneca, Celldex, Genentech, Novartis, Genentech, Sanofi/Regeneron; Other: AstraZeneca, Genentech, Novartis, Sanofi/Regeneron
Douglas	Cox	NA
Daniel	Dasilva	NA
Angela	Davis	NA

Naomi	De Brito	NA
Matthew	Frese	NA
Christina	Gallo	NA
Jo	Shultz	NA
Geoffrey	Wall	Speaker Bureau: Janssen Pharmaceuticals, Tetrphase Pharmaceuticals
Lauren	Welch	NA

How to Get Your Certificate

1. Go to <http://mlg.cmecertificateonline.com/>
2. Click on the “**Enduring Evaluating Treatment Selections for Chronic Spontaneous Urticaria: Managed Care Considerations**” link.
3. Evaluate the meeting.
4. Print all pages of your certificate for your records.

Questions? Email Certificate@AmedcoEmail.com